Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  British Journal of Urology

• Publication date

  1997-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/J.1464-410X.1997.00431.XPMID 9393299
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The treated natural history of high risk superficial bladder cancer: 15-year outcome.

  1997cited by this paper
• Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome.

  1996cited by this paper
• Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.

  1996cited by this paper
• Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder.

  1996cited by this paper
• Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial.

  1995cited by this paper
• Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results.

  1995cited by this paper
• The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years.

  1995cited by this paper
• A simplified grading method of transitional cell carcinoma of the urinary bladder: reproducibility, clinical significance and comparison with other prognostic parameters.

  1994cited by this paper
• Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

  1993cited by this paper
• Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.

  1992cited by this paper
• Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy.

  1992cited by this paper
• Progression of stage T1 bladder tumors after intravesical bacillus Calmette-Guerin.

  1991cited by this paper
• Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer.

  1988cited by this paper
• Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading?

  1987cited by this paper

• PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette–Guérin (BCG) Therapy

  2024cites this paper
• Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette–Guérin instillation in non-muscle-invasive bladder cancer: a network meta-analysis

  2023cites this paper
• A Th2-score in the tumor microenvironment as a predictive biomarker of response to Bacillus Calmette Guérin in patients with non-muscle invasive bladder carcinoma: A retrospective study

  2023cites this paper
• Highlights of the 3rd international BCG symposium: 100th anniversary of the first administration of BCG

  2022cites this paper
• STAG2 Expression is Associated with Adverse Survival Outcomes and Regulates Cell Phenotype in Muscle-invasive Bladder Cancer

  2022cites this paper
• Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers

  2021cites this paper
• Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence

  2020cites this paper
• Usefulness of the inchworm sign on DWI for predicting pT1 bladder cancer progression

  2019cites this paper
• The Surveillance for Muscle-Invasive Bladder Cancer (MIBC)

  2018cites this paper
• ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

  2018cites this paper
• Chapter 20 – Immunotherapy: Bacille Calmette–Guérin

  2018cites this paper
• Prediction models for progression of non‐muscle‐invasive bladder cancer: A review

  2018cites this paper
• Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach

  2017cites this paper
• Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette–Guérin immunotherapy?

  2017cites this paper
• T1G3/T1HG, the Dilemma

  2017cites this paper
• The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer

  2016cites this paper
• Stage T 1 Bladder Cancer – Aspects of Diagnosis and Treatment

  2016cites this paper
• Innovation in Bladder Cancer Immunotherapy

  2016cites this paper
• Stage T1 Bladder Cancer – Aspects of Diagnosis and Treatment

  2016cites this paper
• Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease

  2015cites this paper
• Emerging Approaches to Diagnosis and Treatment of Non–Muscle-Invasive Bladder Cancer

  2015cites this paper
• Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer.

  2015cites this paper
• Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer

  2015cites this paper
• Management of BCG Recurrent Bladder Cancer

  2015cites this paper
• Immunotherapy for Bladder Cancer: Changing the Landscape

  2014cites this paper
• Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.

  2014cites this paper
• Guideline for the Management of Nonmuscle Invasive Bladder Cancer : ( Stages Ta , T 1 , and Tis ) : 2007 Update Bladder Cancer

  2014cites this paper
• Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study.

  2014cites this paper
• Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.

  2014cites this paper
• Update on the management of non-muscle invasive bladder cancer.

  2013cites this paper
• Management of bladder cancer after renal transplantation.

  2013cites this paper
• Determining the role of cystectomy for high-grade T1 urothelial carcinoma.

  2013cites this paper
• Recurrence of high‐risk bladder cancer: A population‐based analysis

  2013cites this paper
• Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?

  2013cites this paper
• Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.

  2013cites this paper
• Gelatinasas (MMP-2, MMP-9) e inhibidor tisular de metaloproteinasas tipo 2 (TIMP-2) como marcadores de diagnóstico y pronóstico en el cáncer de vejiga

  2013cites this paper
• Evaluating the need for transurethral bladder biopsy at first follow up after intravesical BCG therapy for superficial bladder cancer: Preliminary data

  2012cites this paper
• Non-Muscle-Invasive Low- and High-Grade Neoplasia

  2012cites this paper
• Treatment of non-muscle-invasive bladder cancer

  2012cites this paper
• Effet d’agonistes de PPARβ sur l’expression du VEGF (Vascular Endothelial Growth Factor) et des cadhérines E et N dans des modèles de cancers épithéliaux

  2012cites this paper
• Non–Muscle-Invasive Bladder Cancer (Ta, T1, and CIS)

  2012cites this paper
• Predictive Value of Maspin and Ki-67 Expression in Transurethral Resection Specimens in Patients with T1 Bladder Cancer

  2012cites this paper
• Somatic mutation of fibroblast growth factor receptor‐3 (FGFR3) defines a distinct morphological subtype of high‐grade urothelial carcinoma

  2011cites this paper
• Molecular pathology and biomarkers of bladder cancer

  2011cites this paper
• Radical cystectomy for BCG failure: has the timing improved in recent years?

  2011cites this paper
• Anforderungen an eine klinische Datenbank beim Harnblasenkarzinom: Datenbanktheorie und Auswahl der Parameter

  2011cites this paper
• Management of pT1G3 Bladder Cancer

  2011cites this paper
• Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer—evaluation of a large hospital‐based single‐centre series

  2011cites this paper
• Intravesical Immunotherapy: BCG

  2011cites this paper
• Neoplasms of the Kidney and Bladder

  2011cites this paper
• Failure of bacille Calmette‐Guérin in patients with high risk non‐muscle‐invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options

  2010cites this paper
• Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas

  2010cites this paper
• Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate

  2010cites this paper
• Urethral Recurrence of Invasive Carcinoma following BCG Treatment for Bladder Ca in Situ

  2010cites this paper
• The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.

  2010cites this paper
• Retrospective review of radical cystectomies at GSH 1993-2007

  2010cites this paper
• Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.

  2010cites this paper
• An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer.

  2010cites this paper
• Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors.

  2010cites this paper
• [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ].

  2010cites this paper
• Editorial comment on: characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.

  2010cites this paper
• Clusterin Immunoreactivity as a Predictive Factor for Progression of Non-Muscle-Invasive Bladder Carcinoma

  2010cites this paper
• Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer

  2009cites this paper
• Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth

  2009cites this paper
• [Early vs delayed radical cystectomy compared in highgrade superficial bladder tumors].

  2009cites this paper
• Early vs Delayed Radical Cystectomy Compared in Highgrade Superficial Bladder Tumors

  2009cites this paper
• Optimal timing of radical cystectomy for patients with T1 bladder cancer.

  2009cites this paper
• Profilassi endocavitaria nelle neoplasie uroteliali superficiali della vescica: nuovi farmaci

  2009cites this paper
• Low dose BCG regimen in T1 transitional cell carcinoma of the bladder: long term results.

  2009cites this paper
• [Endocavitary prophylaxis of superficial urothelial bladder tumours: new compounds].

  2009cites this paper
• Low dose BCG regimen in T1 transitional cell carcinoma of the bladder: long term results.

  2009cites this paper
• Multiple adverse histological features increase the odds of under staging T1 bladder cancer.

  2009cites this paper
• Intravesical Bacillus Calmette-Guérin Therapy for T1 Superficial Bladder Cancer

  2008cites this paper
• Carcinoma of the bladder

  2008cites this paper
• Bladder Cancer : Review Questions

  2008cites this paper
• Kommentar zu S. Denzinger et al., S. 58

  2008cites this paper
• The optimal management of T1G3 bladder cancer

  2008cites this paper
• IL-18-producing Salmonella inhibit tumor growth

  2008cites this paper
• Tumour growth inhibition by an imidazoquinoline is associated with c‐Myc down‐regulation in urothelial cell carcinoma

  2008cites this paper
• Bacillus Calmette-Guérin in the management of superficial bladder cancer

  2008cites this paper
• Stellenwert der transurethralen Resektion und Instillationstherapie beim Harnblasenkarzinom

  2007cites this paper
• Prognostic value of p53 for high risk superficial bladder cancer with long-term followup.

  2007cites this paper
• Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion.

  2007cites this paper
• The management of superficial bladder cancer

  2007cites this paper
• A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients

  2007cites this paper
• Optimal Management of the T 1 G 3 Bladder Cancer

  2007cites this paper
• Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.

  2007cites this paper
• Routine transurethral biopsy of the bladder is not necessary to evaluate the response to bacillus calmette-guerin therapy.

  2007cites this paper
• Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder.

  2007cites this paper
• Radical Cystectomy Facing Extinction ?

  2007influential citation
• Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth

  2007cites this paper
• Tratamiento de los tumores vesicales T1G3

  2006cites this paper
• Anticancer Activity of Intravesical Glyceryl Monooleate (GMO)-Paclitaxel Therapy in Murine Superficial Transitional Cell Carcinoma Model Induced by BBN

  2006cites this paper
• Intravesical Gemcitabine in BCG-Refractory T1G3 Transitional Cell Carcinoma of the Bladder: A Pilot Study

  2006cites this paper
• Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?

  2006cites this paper
• Controversial issues and optimal management of stage T1G3 bladder cancer

  2006cites this paper
• Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer

  2006cites this paper
• [Management of T1G3 tumours of the bladder].

  2006cites this paper
• PROGNOSTIC SIGNIFICANCE OF ABSENCE OF PROPER MUSCLE IN THE RESECTED SPECIMEN OF PRIMARY T1G3 BLADDER CANCER

  2006cites this paper
• The role of imaging in the surveillance of urologic malignancies.

  2006cites this paper